Business Context and Reporting Period
Company: E. I. du Pont de Nemours and Company (DuPont)
Filing Type: Form 8-K (Current Report)
Reporting Period: First Quarter 2001 (Ended March 31, 2001)
Date of Report: April 24, 2001
DuPont reported first-quarter earnings in line with expectations but significantly below the prior year due to a global economic slowdown, reduced sales volumes, higher raw material costs, and a weaker Pharmaceuticals segment. The company is implementing restructuring initiatives to align resources with business missions, with associated one-time charges expected in the second quarter.
Key Financial Metrics
| Metric | Q1 2001 | Q1 2000 | Change |
|---|---|---|---|
| Consolidated Sales | $6.9 billion | $7.6 billion | (10%) |
| Segment Sales | $7.6 billion | $8.3 billion | (9%) |
| Net Income (Reported) | $495 million | $803 million | (38%) |
| Net Income (Underlying) | $567 million | $898 million | (37%) |
| EPS (Diluted, Reported) | $0.47 | $0.76 | (38%) |
| EPS (Diluted, Underlying) | $0.54 | $0.85 | (36%) |
| Underlying ATOI | $734 million | $1.09 billion | (33%) |
| ATOI Margin | 10% | 13% | (3 pts) |
| EBITDA | $1.5 billion | $2.1 billion | (27%) |
Debt and Liquidity: The filing text does not provide specific values for total debt, cash balances, or liquidity ratios.
Material Changes vs. Prior Period
- Sales Decline: Segment sales fell 9% year-over-year, driven by a 7% volume decline and a 2% reduction in U.S. dollar selling prices. Adverse currency effects (weaker euro and yen) reduced worldwide segment sales by 3%.
- Profitability: Underlying After-Tax Operating Income (ATOI) dropped 33%. Pharmaceuticals accounted for approximately one-third of this decline, posting a $64 million loss compared to $54 million in profit the prior year.
- Cost Pressures: Excluding Pharmaceuticals, ATOI reductions included a $165 million impact from higher raw material costs (notably natural gas and chlorine) and $100 million from lower sales volume.
- Segment Performance:
- Nylon Enterprise: ATOI declined 86% due to a 40% increase in raw material costs and 15% lower volumes.
- Performance Coatings & Polymers: Sales down 12% and ATOI down 26% due to lower vehicle builds and higher raw material costs.
- Pioneer: Earnings increased 17% due to improved margins and product mix, offsetting weak currency impacts.
Guidance, Outlook, and Risks
Outlook: Management anticipates the global economic slowdown will impact the manufacturing sector through the second quarter and potentially into the second half of 2001.
- Q2 Expectations: Continued volume pressure in U.S. chemical and materials businesses; stabilizing but elevated energy/raw material costs; negative revenue comparisons in Europe and Asia due to the strong U.S. dollar.
- Pharmaceuticals: Sales and earnings expected to improve in Q2, though ATOI losses are anticipated. A return to normal levels is expected in the second half.
- Agriculture: Full-year outlook is moderately negative versus 2000 due to a difficult U.S. farm economy, poor weather, and high fertilizer costs reducing corn acreage.
Risks and Contingencies:
- Restructuring: One-time charges for business restructurings and personnel reductions will be taken in the second quarter.
- Accounting Changes: Adoption of SFAS 133 (Derivatives) effective Jan 1, 2001, resulted in a $11 million after-tax cumulative effect charge.
- Market Risks: Exposure to foreign currency exchange rates, inflation, interest rates, and competitive pressures.
Investor Verification Checklist
- Verify the magnitude of Q2 one-time restructuring charges and their impact on cash flow.
- Monitor the trajectory of raw material costs, specifically natural gas and chlorine, and their pass-through to selling prices.
- Assess the recovery timeline for the Pharmaceuticals segment, particularly regarding wholesaler inventory levels and Sustiva/Cardiolite demand.
- Review the impact of the strong U.S. dollar on European and Asian revenue comparisons in upcoming quarters.
- Confirm the status of the "Six Sigma" initiative benefits ($490 million annualized pretax benefit) against actual cost savings.